Intellectual Property and Collaborative Agreements (Details Narrative) - USD ($)					1 Months Ended					12 Months Ended
	Jul. 31, 2016	Apr. 30, 2016	Mar. 31, 2016	Feb. 29, 2016	Jul. 31, 2017	Jun. 30, 2017	Apr. 30, 2017	Feb. 28, 2017	Nov. 30, 2016	Dec. 31, 2017	Sep. 30, 2016
Sale of common stock to related party, shares		47,468		20,548			6,928
Sale of common stock to related party		$ 75,000		$ 58,000
License fee	$ 350,000		$ 250,000
License and success-based milestones			$ 40,000,000
Number of value issued for equity components										$ 178,784
Purchase price										250,000
Sale of stock price per share							$ 2.90
Oncotelic, Inc. [Member]
Purchase price					$ 500,000
License Agreement [Member]
Accounts receivable											$ 50,000
Number of shares issued for equity components									11,905
Number of value issued for equity components									$ 15,000
Sale of stock price per share					$ 5.10
License Agreement [Member] | Oncotelic, Inc. [Member]
Purchase price, shares					49,019
Purchase price					$ 250,000
Sale of stock price per share					$ 5.10
Commercial sales of licensed products					$ 90,000,000
License Agreement [Member] | Lipo Medics [Member]
Sale of common stock to related party								$ 500,000
Number of shares issued for equity components								86,207
Number of value issued for equity components								$ 250,000
Revenue recognition, milestone method, milestone								$ 90,000,000
Weighted average price per share								$ 2.90
Intellectual property collaboration description								In consideration Lipomedics agreed to the following fee schedule: 1) Evaluations License Fee. Simultaneous with the execution and delivery of the License Agreement, Lipomedics shall enter into a Stock Purchase Agreement in form and substance reasonably acceptable to Marina and Lipomedics, pursuant to which Marina will sell to Lipomedics shares of the common stock of Marina for an aggregate purchase price of $0.25 million, with the purchase price for each share of Marina common stock being $2.90. 2) Commercial License Fee. Unless the License Agreement is earlier terminated, within thirty (30) days following Lipomedics’s delivery of an Evaluation Notice advising that it intends to pursue, or cause to be pursued, further development and commercialization of Licensed Products. 3) For up to and including three Licensed Products, Lipomedics shall pay to Marina a milestone (collectively the “Sales Milestones”) of $10 million upon reaching Commercial Sales in the Territory in any given twelve month period equal to or greater than $500 million for a given Licensed Product and of $20 million upon reaching Commercial Sales in any given twelve month period equal to or greater than $1 million for such Licensed Product, such payments to be made within thirty (30) days following the month in which such Commercial Sale targets are met.
Licensing Agreement [Member] | March 16, 2018 [Member]
Upfront payment of future consideration										$ 200,000
Purchase Agreement [Member] | Symplmed Pharmaceuticals LLC [Member]
Purchase price					$ 75,000
Upfront payment of future consideration						$ 620,000